Trials / Recruiting
RecruitingNCT05767307
Danish Prostate Cancer Consortium Study-1
Danish Prostate Cancer Consortium Study-1 (DPCC-1): Multicenter Development of Liquid Biopsy Biomarkers for Early Detection of Prostate Cancer.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,500 (estimated)
- Sponsor
- Aarhus University Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate if a new promising microRNA-based urine biomarker test for prostate cancer, called uCaP, is better than the current standard test (PSA) to identify men who would benefit from an MRI scan of the prostate. The study will include 2,500 men referred to MRI of the prostate at three major hospital centers in Denmark (Aarhus, Odense, and Herlev) and compare the accuracy of uCaP to PSA. Based on preliminary data it is expected that uCaP will be \>20% better than PSA at identifying treatment-requiring cancer. Hence, uCaP could help to better pre-select men for MRI and thereby reduce unnecessary MRI scans, unnecessary prostate biopsies, as well as overdiagnosis and overtreatment of indolent PCs, while maintaining high sensitivity for aggressive PC that needs early detection and early treatment.
Conditions
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2025-12-31
- Completion
- 2040-01-01
- First posted
- 2023-03-14
- Last updated
- 2023-11-29
Locations
3 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05767307. Inclusion in this directory is not an endorsement.